drugset / Trial / NCT04401293

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293

Phase 3 Completed 257 enrolled Northwell Health
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than prophylaxis with institutional standard of care with prophylactic to intermediate-doses of UFH or LMWH

Timeline

Start
2020-04-26
Primary completion
2021-05-14
Completion
2021-05-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Enoxaparin sodium Other / unclassified 0.5 mg/kg Subcutaneous
Subject Enoxaparin sodium Other / unclassified 1 mg/kg Subcutaneous
Subject Enoxaparin sodium Other / unclassified 30 mg Subcutaneous
Subject Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Comparator Heparin Other / unclassified 5000 iu Subcutaneous
Comparator Heparin Other / unclassified 7500 iu Subcutaneous
Comparator Prophylactic/Intermediate Dose Enoxaparin Unknown 2500 iu
Comparator Prophylactic/Intermediate Dose Enoxaparin Unknown 5000 iu

Indications